1. Calabrò, L, Peters, S, Soria, J-C, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020; 8: 542–544.
Google Scholar | Crossref | Medline2. Fox, T, Troy-Barnes, E, Kirkwood, A, et al. Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy. Br J Hematol 2020; 191: 194–206.
Google Scholar | Crossref | Medline3. von Lilienfeld-Toal, M, Vehreschild, JJ, Cornely, O, et al. Frequently asked questions regarding SARS-CoV-2 in cancer patients: recommendations for clinicians caring for patients with malignant diseases. Leukemia 2020; 34: 1487–1494.
Google Scholar | Crossref | Medline4. Alhalabi, O, Subbiah, V. Managing cancer care during the COVID-19 pandemic and beyond. Trends Cancer 2020; 6: 533–535.
Google Scholar | Crossref | Medline5. Alshamrani, M, Al Harbi, A, Alkhudair, N, et al. Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations. J Oncol Pharm Pract 2020; 26: 1429–1440.
Google Scholar | SAGE Journals6. Masoudi, S, Nemati, AH, Fazli, HR, et al. An increased level of aryl hydrocarbon receptor in patients with pancreatic cancer. Middle East J Dig Dis 2019; 11: 38–44.
Google Scholar | Crossref | Medline7. Salunke, AA, Nandy, K, Pathak, SK, et al. Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr 2020; 14: 1431–1437.
Google Scholar | Crossref | Medline8. Liang, W, Guan, W, Chen, R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335–337.
Google Scholar | Crossref | Medline9. Bonomi, L, Ghilardi, L, Arnoldi, E, et al. A rapid fatal evolution of coronavirus disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab. J Thorac Oncol 2020;15: e83–e85.
Google Scholar | Crossref | Medline10. Gatfield, E, Mukesh, M, Loo, S. Adjuvant systemic anti-cancer therapy in early breast cancer during the COVID-19 pandemic: differences between clinicians and patients in perception of treatment risks and benefits. Clin Oncol 2020; 32: e218.
Google Scholar | Crossref11. Maio, M, Hamid, O, Larkin, J, et al. Immune checkpoint inhibitors for cancer therapy in the COVID-19 era. Clin Cancer Res 2020; 26: 4201–4205.
Google Scholar | Crossref | Medline12. Schreiber, RD, Old, LJ, Smyth, MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331: 1565–1570.
Google Scholar | Crossref | Medline13. Mohamadkhani, A, Pourshams, A, Viti, J, et al. Pancreatic cancer is associated with peripheral leukocyte oxidative DNA damage. Asian Pacific J Cancer Prev 2017; 18: 1349.
Google Scholar | Medline14. Bi, D, Wen, L, Wu, Z, et al. GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer’s disease. Alzheimer Dement 2020; 16: 1312–1329.
Google Scholar | Crossref | Medline15. Chamilos, G, Lionakis, MS, Kontoyiannis, DP. Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)? Clin Infect Dis 2021; 72: 351–356.
Google Scholar | Crossref | Medline16. Kattan, J, Kattan, C, Assi, T. Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection? Immunotherapy 2020; 12: 351–354.
Google Scholar | Medline17. Cavalcanti, IDL, Soares, JCS. Impact of COVID-19 on cancer patients: a review. Asia-Pacific J Clin Oncol 2021; 17: 186–192.
Google Scholar | Crossref | Medline18. DuBois, RN . COVID-19, cancer care and prevention. Cancer Prev Res 2020; 13: 889–892.
Google Scholar | Crossref19. Nahm, S, Rembielak, A, Peach, H, et al. Consensus guidelines for the management of melanoma during the COVID-19 pandemic: surgery, systemic anti-cancer therapy, radiotherapy and follow-up. Clin Oncol 2021; 33: e54–e57.
Google Scholar | Crossref20. Corrie, PG . Cytotoxic chemotherapy: clinical aspects. Medicine 2008; 36: 24–28.
Google Scholar | Crossref21. Jones, R, Ocen, J. Cytotoxic chemotherapy: clinical aspects. Medicine 2020; 48: 97–102.
Google Scholar | Crossref22. Peters, GJ . Novel developments in the use of antimetabolites. Nucleosides Nucleotides Nucleic Acids 2014; 33: 358–374.
Google Scholar | Crossref | Medline23. Schirrmacher, V . From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol 2019; 54: 407–419.
Google Scholar | Medline24. Schütte, J, Seeber, S. Tumordefinitionen/Remissionskriterien. Therapiekonzepte Onkologie. Springer; 1993: 3–12.
Google Scholar25. Ghiringhelli, F, Apetoh, L. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. Exp Rev Clin Immunol 2014; 10: 19–30.
Google Scholar | Crossref | Medline26. Duarte, MBO, Leal, F, Argenton, JLP, et al. Outcomes of covid-19 patients under cytotoxic cancer chemotherapy in Brazil. Cancers 2020; 12: 3490.
Google Scholar | Crossref27. Williams, M, Le Calvez, K, Mi, E, et al. Estimating the risks from COVID-19 infection in adult chemotherapy patients. MedRxiv 2020.
Google Scholar28. Tian, J, Yuan, X, Xiao, J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 893–903.
Google Scholar | Crossref | Medline29. Yang, K, Sheng, Y, Huang, C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 904–913.
Google Scholar | Crossref | Medline30. Shams, S, Mansoor, K. COVID-19 and self-care measures by chemotherapy patients. Asia-Pacific J Oncol Nurs 2020; 7: 310.
Google Scholar | Crossref | Medline31. Al-Shamsi, HO, Alhazzani, W, Alhuraiji, A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist 2020; 25: e936.
Google Scholar | Crossref | Medline32. Jee, J, Foote, MB, Lumish, M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol 2020; 38: 3538–3546.
Google Scholar | Crossref | Medline33. Lee, LY, Cazier, JB, Starkey, T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395: 1919–1926.
Google Scholar | Crossref | Medline34. Kanjanapan, Y, Yip, D. Considerations for cancer immunotherapy during the COVID-19 pandemic. Med J Aust 2020; 213: 390–392.
Google Scholar | Crossref | Medline35. Akula, SM, Abrams, SL, Steelman, LS, et al. Cancer therapy and treatments during COVID-19 era. Adv Biol Regul 2020; 100739.
Google Scholar | Crossref | Medline36. Harris, TJ, Drake, CG. Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer 2013; 1: 1–9.
Google Scholar | Crossref | Medline37. Sathyanarayanan, V, Neelapu, SS. Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol Oncol 2015; 9: 2043–2053.
Google Scholar | Crossref | Medline38. Oldham, RK, Dillman, RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008; 26: 1774–1777.
Google Scholar | Crossref | Medline39. Şakalar, Ç, İzgi, K, Canatan, H. Kanser immün terapi ve monoklonal antikorlar. Fü Sağ Bil Tıp Derg 2013; 27: 105–110.
Google Scholar40. Mayor, M, Yang, N, Sterman, D, et al. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardio-Thoracic Surg 2015; 49: 1324–1333.
Google Scholar | Crossref | Medline41. Papaioannou, NE, Beniata, OV, Vitsos, P, et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med 2016; 4.
Google Scholar | Medline42. Agarwal, S, June, CH. Harnessing CAR T cell insights to develop treatments for hyperinflammatory responses in COVID-19 patients. Cancer Disc 2020; 6.
Google Scholar43. Pleyer, C, Ali, MA, Cohen, JI, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood 2021; 137: 185–189.
Google Scholar | Crossref | Medline44. Houot, R, Levy, R, Cartron, G, et al. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer 2020; 136: 4–6.
Google Scholar | Crossref | Medline45. Baker, D, Roberts, CAK, Pryce, G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020; 202: 149–161.
Google Scholar | Crossref | Medline46. Yarza, R, Bover, M, Paredes, D, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 2020; 135: 242–250.
Google Scholar | Crossref | Medline47. Terpos, E, Ntanasis-Stathopoulos, I, Elalamy, I, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95: 834–847.
Google Scholar | Crossref | Medline48. Jiao, X, Nawab, O, Patel, T, et al. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res 2019; 79: 4801–4807.
Google Scholar | Crossref | Medline49. Richardson, P, Griffin, I, Tucker, C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395: e30.
Google Scholar | Crossref50. Stebbing, J, Phelan, A, Griffin, I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20: 400–402.
Google Scholar | Crossref | Medline51. Velasco-Velázquez, M, Jiao, X, De La Fuente, M, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72: 3839–3850.
Google Scholar | Crossref | Medline52. Lederman, MM, Penn-Nicholson, A, Cho, M, et al. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296: 815–826.
Google Scholar | Crossref | Medline53. Asokan, I, Rabadia, SV, Yang, EH. The COVID-19 pandemic and its impact on the cardio-oncology population. Curr Oncol Rep 2020; 22: 60.
Google Scholar | Crossref | Medline54. Marovich, M, Mascola, JR, Cohen, MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA 2020; 324: 131–132.
Google Scholar | Crossref | Medline55. Patterson, BK, Seethamraju, H, Dhody, K, et al. Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. medRxiv 2020.